EXPONENT INC
For the period ended Sep 27, 2024. Filed Nov 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 27, 2024 · Filed Nov 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Unaudited Condensed Consolidated Financial Statements
Note 1: Basis of Presentation
Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December.
The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three and nine months ended September 27, 2024 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2023, which was filed with the U.S. Securities and Exchange Commission on February 23, 2024 and amended on April 17, 2024.
The unaudited condensed consolidated financial statements include the accounts of Exponent and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates.
Note 2: Revenue Recognition
Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 –Revenue from Contracts with Customers, which states that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided) then the entity may recognize revenue in the amount to which the entity has a right to invoice.
The following table discloses the percentage of the Company’s revenue generated from time and materials contracts:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 | |
| Engineering & Other Scientific | 63% | 61% | 63% | 63% |
| Environmental and Health | 15% | 15% | 16% | 15% |
| Total time and materials revenues | 78% | 76% | 79% | 78% |
For fixed-price contracts, the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company’s rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company’s estimate of the total labor hours at standard rates it expects to
-9 - incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides.
The following table discloses the percentage of the Company’s revenue generated from fixed price contracts:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 | |
| Engineering & Other Scientific | 21% | 23% | 20% | 20% |
| Environmental and Health | 1% | 1% | 1% | 2% |
| Total fixed price revenues | 22% | 24% | 21% | 22% |
Deferred revenues represent amounts billed to clients in advance of services provided. During the third quarter of 2024, $3,666,000 of revenues were recognized that were included in the deferred revenue balance at June 28, 2024. During the first nine months of 2024, $12,974,000 of revenues were recognized that were included in the deferred revenue balance at December 29, 2023.
Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third- party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $2,689,000 and $2,379,000 during the third quarter of 2024 and 2023, respectively, and $9,222,000 and $10,727,000 during the first nine months of 2024 and 2023, respectively.
-10 -
Note 3: Fair Value Measurements
The Company measures certain financial assets and liabilities at fair value on a recurring basis, including money market securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three and nine months ended September 27, 2024 and September 29, 2023. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these certain financial assets and liabilities was determined using the following inputs at September 27, 2024:
| Fair Value Measurements at Reporting Date Using | ||||||
|---|---|---|---|---|---|---|
| (In thousands) · Total · Quoted Prices inActive Marketsfor IdenticalAssets (Level 1) · Significant OtherObservable Inputs(Level 2) · SignificantUnobservableInputs(Level 3) | ||||||
| Assets | ||||||
| Money market securities (1) | $56,869 | $56,869 | $ | - | $ | - |
| Fixed income trading securities held in deferred compensation plan (2) | 38,935 | 38,935 | - | - | ||
| Equity trading securities held in deferred compensation plan (2) | 87,859 | 87,859 | - | - | ||
| Total | $183,663 | $183,663 | $ | - | $ | - |
| Liabilities | ||||||
| Deferred compensation plan (3) | 127,722 | 127,722 | - | - | ||
| Total | $127,722 | $127,722 | $ | - | $ | - |
(1)
Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.
(2)
Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.
(3)
Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.
-11 -
The fair value of these certain financial assets and liabilities was determined using the following inputs at December 29, 2023:
| Fair Value Measurements at Reporting Date Using | ||||||
|---|---|---|---|---|---|---|
| (In thousands) · Total · Quoted Prices inActive Marketsfor IdenticalAssets (Level 1) · Significant OtherObservable Inputs(Level 2) · SignificantUnobservableInputs(Level 3) | ||||||
| Assets | ||||||
| Money market securities (1) | $54,686 | $54,686 | $ | - | $ | - |
| Fixed income trading securities held in deferred compensation plan (2) | 36,788 | 36,788 | - | - | ||
| Equity trading securities held in deferred compensation plan (2) | 78,399 | 78,399 | - | - | ||
| Total | $169,873 | $169,873 | $ | - | $ | - |
| Liabilities | ||||||
| Deferred compensation plan (3) | 116,564 | 116,564 | - | - | ||
| Total | $116,564 | $116,564 | $ | - | $ | - |
(1)
Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.
(2)
Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.
(3)
Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.
Money market securities as of September 27, 2024 and December 29, 2023 represent obligations of the United States Treasury. Fixed income and equity trading securities represent mutual funds held in the Company’s deferred compensation plan. See Note 6 for additional information about the Company’s deferred compensation plan.
Cash and cash equivalents consisted of the following as of September 27, 2024:
| Gross · Gross | ||||||
|---|---|---|---|---|---|---|
| Amortized · Unrealized · Unrealized · Estimated | ||||||
| (In thousands) · Cost · Gains · Losses · Fair Value | ||||||
| Classified as current assets: | ||||||
| Cash | $162,839 | $ | - | $ | - | $162,839 |
| Cash equivalents: | ||||||
| Money market securities | 56,869 | - | - | 56,869 | ||
| Total cash equivalents | 56,869 | - | - | 56,869 | ||
| Total cash and cash equivalents | 219,708 | - | - | 219,708 | ||
Cash and cash equivalents consisted of the following as of December 29, 2023:
| Amortized · Unrealized · Unrealized · Estimated | ||||||
|---|---|---|---|---|---|---|
| (In thousands) · Cost · Gains · Losses · Fair Value | ||||||
| Classified as current assets: | ||||||
| Cash | $132,464 | $ | - | $ | - | $132,464 |
| Cash equivalents: | ||||||
| Money market securities | 54,686 | - | - | 54,686 | ||
| Total cash equivalents | 54,686 | - | - | 54,686 | ||
| Total cash and cash equivalents | $187,150 | $ | - | $ | - | $187,150 |
-12 -
At September 27, 2024 and December 29, 2023, the Company did not have any assets or liabilities valued using significant unobservable inputs.
The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at September 27, 2024 and December 29, 2023, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at September 27, 2024 and December 29, 2023 approximates their carrying value as reported on the Company’s unaudited condensed consolidated balance sheet.
Note 4: Net Income Per Share
Basic per share amounts are computed using the weighted-average number of shares of common stock outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of shares of common stock outstanding during the period and, when dilutive, the weighted-average number of potential shares of common stock from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method.
The following schedule reconciles the shares used to calculate basic and diluted net income per share:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Shares used in basic per share computation | 51,177 | 51,203 | 51,098 | 51,197 |
| Effect of dilutive common stock options outstanding | 175 | 183 | 172 | 195 |
| Effect of dilutive restricted stock units outstanding | 270 | 259 | 257 | 288 |
| Shares used in diluted per share computation | 51,622 | 51,645 | 51,527 | 51,680 |
Common stock options to purchase 30,000 and 63,333 shares were excluded from the diluted per share calculation for the three months ended September 27, 2024 and September 29, 2023, respectively, due to their anti-dilutive effect. Common stock options to purchase 63,333 and 24,835 shares were excluded from the diluted per share calculation for the nine months ended September 27, 2024 and September 29, 2023, respectively, due to their anti-dilutive effect.
Note 5: Stock-Based Compensation
Restricted Stock Units
Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company’s common stock for each fully vested restricted stock unit four years from the date of grant. Each individual who receives a fully vested restricted stock unit award is also granted a matching number of unvested restricted stock unit awards. Unvested restricted stock unit awards are also granted for select new hires and promotions. These unvested restricted stock unit awards generally cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company’s common stock for each restricted stock unit award provided the holder of each award has met certain employment conditions. In the case of retirement at 59½ years or older, all unvested restricted stock unit awards will vest, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company.
The value of these restricted stock unit awards is determined based on the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The
-13 -
Company recorded stock-based compensation expense associated with accrued bonus awards of $2,842,000 and $2,583,000 during the three months ended September 27, 2024 and September 29, 2023, respectively. For the nine months ended September 27, 2024 and September 29, 2023, the Company recorded stock-based compensation expense associated with accrued bonus awards of$9,238,000 and $8,242,000, respectively. The value of the unvested restricted stock unit awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of $2,255,000 and $2,038,000 during the three months ended September 27, 2024 and September 29, 2023, respectively. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of$8,089,000 and $8,124,000 during the nine months ended September 27, 2024 and September 29, 2023, respectively.
Stock Options
Stock options are granted for terms often years and generally vest 25% per year over afour-year period from the grant date. Unvested stock option awards will continue to vest in the case of retirement at 59½ years or older, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of the unvested stock option awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with stock option grants of $368,000 and $270,000 during the three months ended September 27, 2024 and September 29, 2023, respectively. The Company recorded stock-based compensation expense associated with stock option grantsof $1,055,000 and $811,000 during the nine months ended September 27, 2024 and September 29, 2023, respectively.
The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.
The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company’s common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders’ dividend equivalent rights.
The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.
Note 6: Deferred Compensation Plans
The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company’s creditors. As of September 27, 2024 and December 29, 2023, the invested amounts under the plans totaled $126,794,000 and $115,187,000, respectively, and are recorded in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. These assets are classified as trading securities and are recorded at fair value with changes recorded as adjustments to miscellaneous income (loss), net.
As of September 27, 2024 and December 29, 2023, vested amounts due under the plans totaled$127,722,000 and $116,564,000, respectively, and are recorded within accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheets. Changes in the liability are recorded as adjustments to compensation expense. During the three months ended September 27, 2024,
-14 - the Company recognized additional compensation expense of $7,157,000 as a result of changes in the market value of the trust assets with the same amount being recorded as gain in miscellaneous income (loss), net. During the three months ended September 29, 2023, the Company recognized a reduction in compensation expense of $2,769,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a loss in miscellaneous income (loss), net. During the nine months ended September 27, 2024, the Company recognized additional compensation expense of$14,299,000 as a result of changes in the market value of the trust assets with the same amount being recorded as income in miscellaneous income, net. During the nine months ended September 29, 2023, the Company recognized additional compensation expense of $5,271,000 as a result of changes in the market value of the trust assets with the same amount being recorded as income in miscellaneous income (loss), net.
Note 7: Supplemental Cash Flow Information
The following is supplemental disclosure of cash flow information:
| Nine Months Ended | ||
|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 |
| Cash paid during period: | ||
| Income taxes | $29,060 | $27,753 |
| Non-cash investing and financing activities: | ||
| Vested stock unit awards issued to settle accrued bonuses | 10,846 | 10,497 |
| Right-of-use asset obtained in exchange for operating lease obligations | 56,714 | 13,803 |
| Leasehold improvements obtained in exchange for right-of-use asset | - | 3,219 |
| Accrual for capital expenditures as of period end | 537 | 618 |
Note 8: Accounts Receivable, Net
At September 27, 2024 and December 29, 2023, accounts receivable, net, was comprised of the following:
| September 27, | December 29, | |
|---|---|---|
| (In thousands) | 2024 | 2023 |
| Billed accounts receivable | $117,746 | $128,052 |
| Unbilled accounts receivable | 57,353 | 44,589 |
| Allowance for contract losses and doubtful accounts | (6,481) | (5,281) |
| Total accounts receivable, net | $168,618 | $167,360 |
The Company maintains allowances for estimated losses over the remaining contractual life of its receivables resulting from the inability of customers to meet their financial obligations or for disputes that affect the Company’s ability to fully collect amounts due. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations or aware of a dispute with a specific customer, a specific allowance is recorded to reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers the Company recognizes allowances for doubtful accounts based upon historical write-offs, customer concentration, customer creditworthiness, current economic conditions, aging of amounts due and future expectations.
A reconciliation of the beginning and ending amount of the allowance for contract losses and doubtful accounts is as follows (in thousands):
| Balance at December 29, 2023 | $5,281 |
|---|---|
| Provision for contract losses and doubtful accounts | 3,140 |
| Write-offs | (1,940) |
| Balance at September 27, 2024 | $6,481 |
-15 -
Note 9: Segment Reporting
The Company hastwo reportable operating segments based on two primary areas of service. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and Health segment provides services in the areas of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and the impact on both human health and the environment. Our Chief Executive Officer, the chief operating decision maker, reviews revenues and operating income for each of our reportable segments, but does not review total assets in evaluating segment performance and capital allocation.
Segment information for the three and nine months ended September 27, 2024 and September 29, 2023 follows:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Engineering and Other Scientific | $115,244 | $110,857 | $355,193 | $344,552 |
| Environmental and Health | 21,035 | 22,479 | 66,555 | 69,314 |
| Total revenues | $136,279 | $133,336 | $421,748 | $413,866 |
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Engineering and Other Scientific | $40,292 | $38,734 | $132,687 | $121,064 |
| Environmental and Health | 7,547 | 7,475 | 23,042 | 22,550 |
| Total segment operating income | 47,839 | 46,209 | 155,729 | 143,614 |
| Corporate operating expense | (21,992) | (12,276) | (63,425) | (50,686) |
| Total operating income | $25,847 | $33,933 | $92,304 | $92,928 |
Certain operating expenses are excluded from the Company’s measure of segment operating income. These expenses include costs associated with its human resources, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with its deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in its allowance for contract losses and doubtful accounts.
Capital Expenditures
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Engineering and Other Scientific | $887 | $541 | $1,769 | $3,210 |
| Environmental and Health | - | 25 | 74 | 139 |
| Total segment capital expenditures | 887 | 566 | 1,843 | 3,349 |
| Corporate capital expenditures | 1,339 | 1,248 | 2,899 | 13,893 |
| Total capital expenditures | $2,226 | $1,814 | $4,742 | $17,242 |
Certain capital expenditures associated with the Company’s corporate cost centers and the related depreciation are excluded from the Company’s segment information.
-16 -
Depreciation and Amortization
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Engineering and Other Scientific | $1,735 | $1,750 | $5,128 | $4,428 |
| Environmental and Health | 50 | 53 | 154 | 155 |
| Total segment depreciation and amortization | 1,785 | 1,803 | 5,282 | 4,583 |
| Corporate depreciation and amortization | 604 | 558 | 1,917 | 1,952 |
| Total depreciation and amortization | $2,389 | $2,361 | $7,199 | $6,535 |
No single client comprised more than 10%of the Company’s revenues during the three and nine months ended September 27, 2024. No single client comprised more than 10% of the Company’s revenues during the three and nine months ended September 29, 2023.
Note 10: Leases
The Company determines if an arrangement is a lease at the inception of the arrangement. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liabilities in the Company’s condensed consolidated balance sheet. The Company does not have any finance leases as of September 27, 2024.
ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statements of cash flows.
The Company leases office, laboratory, and storage space in 13 states and the District of Columbia, as well as in China, Hong Kong, Singapore, Switzerland, and the United Kingdom. Leases for these office, laboratory, and storage facilities have terms generally ranging betweenone andten years. Some of these leases include options to extend or terminate the lease, none of which are currently included in the lease term as the Company has determined that exercise of these options is not reasonably certain.
The Company has a Test and Engineering Center on 147 acres of land in Phoenix, Arizona. The Company leases this land from the State of Arizona under a 30-year lease agreement that expires in January of 2028 and hasoptions to renew fortwo fifteen-year periods. On June 19, 2024, the Company entered into an agreement with the State of Arizona to extend this lease for 15 years beginning on January 17, 2028. The Company is currently obligated to make payments under the lease of $1,009,000 per year, which obligation will continue at that level until January 16, 2028. Beginning on January 17, 2028, the Company’s payments under the lease will increase to approximately $6,183,000 per year for the 15-year extension term with adjustments to the annual rent payment in 2033 and 2038 based on the consumer price index. As a result of this extension, the Company added an additional right-of-use asset in exchange for an operating lease liability of $48,683,000 during the second quarter of 2024. As of September 27, 2024, the Company has determined that the exercise of the second renewal option is not reasonably certain and thus that extension is not included in the lease term.
The Company’s equipment leases are included in the ROU asset and liability balances, but are not material.
The Company leases excess space in its Silicon Valley and Natick facilities. Rental income of $742,000 and $882,000 wasincluded in other income for the three months ended September 27, 2024 and September 29, 2023,
-17 - respectively. Rental income of $2,511,000 and $2,491,000 was included in other income for the nine months ended September 27, 2024 and September 29, 2023, respectively.
The components of lease expense included in other operating expenses on the condensed consolidated statements of income were as follows:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Operating lease cost | $3,251 | $2,094 | $7,758 | $5,659 |
| Variable lease cost | 352 | 378 | 1,100 | 1,251 |
| Short-term lease cost | 378 | 256 | 1,028 | 937 |
Supplemental cash flow information related to operating leases was as follows:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| (In thousands) | September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 |
| Cash paid for amounts included in the measurement of operating lease liabilities | $1,654 | $1,715 | $6,002 | $5,516 |
Supplemental balance sheet information related to operating leases was as follows:
| September 27, 2024 | September 29, 2023 | |
|---|---|---|
| Weighted Average Remaining Lease Term | 14.0 years | 6.4 years |
| Weighted Average Discount Rate | 6.2% | 5.1% |
Maturities of operating lease liabilities as of September 27, 2024:
| Operating | |
|---|---|
| (In thousands) | Leases |
| 2024 (excluding the nine months ended September 27, 2024) | $1,538 |
| 2025 | 7,803 |
| 2026 | 7,460 |
| 2027 | 6,183 |
| 2028 | 9,645 |
| Thereafter | 98,461 |
| Total lease payments | 131,090 |
| Less imputed interest | (50,228) |
| Total lease liability | $80,862 |
Note 11: Contingencies
The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.
-18 -
Note 12: Subsequent Events
On October 24, 2024, the Company’s Board of Directors announced a cash dividend of $0.28 per share of the Company’s common stock, payable December 20, 2024, to stockholders of record as of December 6, 2024.
-19 -
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.